Gilead Secures Approvals for Arcellx Acquisition Deal
FOSTER CITY, Calif., April 17, 2026 Gilead Sciences, Inc. has announced that it has obtained all required regulatory approvals...
Gilead Sciences
Advertisement
Kymera-Gilead Deal Advances CDK2 Cancer Therapy
WATERTOWN, Massachusetts, April 9, 2026 Kymera Therapeutics has announced that Gilead Sciences has exercised its option to exclusively license...
Gilead Acquires Tubulis to Boost Oncology Pipeline
FOSTER CITY, California, United States & MUNICH, Germany, April 7, 2026 Gilead Sciences, Inc. announced a definitive agreement to...
Gilead to Acquire Ouro for $2.1B Autoimmune Pipeline Boost
FOSTER CITY, CALIFORNIA, March 24, 2026 Gilead Sciences has announced a definitive agreement to acquire Ouro Medicines in a...
Gilead to Acquire Arcellx in $7.8B Cell Therapy Deal
February 24, 2026 — Foster City, CA & Redwood City, CA:Gilead Sciences, Inc. (Nasdaq: GILD) today revealed a definitive...
Advertisements
Gilead–U.S. Pact Aims to Cut Drug Costs for Americans
December 22, 2025 | Foster City, California — Gilead Sciences announced a three-year agreement with the U.S. Government designed...
HOOKIPA Completes Sale of HBV and HIV Programs to Gilead Sciences
NEW YORK and VIENNA – October 31, 2025 — HOOKIPA Pharma Inc. (OTC: HOOK) announced the completion of the...
Gilead Showcases New Virology Data Spanning HIV, Hepatitis, and respiratory diseases
Foster City, California – October 20, 2025 — Gilead Sciences, Inc. (Nasdaq: GILD) announced that it will present new...
Gilead Advances HIV Innovation with Breakthrough EACS 2025 Data
Barcelona, Spain – October 15, 2025 – Gilead Sciences, Inc. (NASDAQ: GILD) unveiled new data across its HIV prevention...
Advertisement
